RxDoctor Payments Data

John Delmas, MD

Internal Medicine · Mobile, ALNPI 1568476588

Payments from drug & device makers

$2,150in general payments, 2019–2025

Across 131 payments — averaging $16.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$305
  • Daiichi Sankyo Inc.$280
  • Amgen$277
  • GSK$257
  • Lilly USA, LLC$185
  • Novo Nordisk$156
  • plus $691 from 15 others

What the payments were for

  • Food & beverage$2,150100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,150 in reported general payments places this provider in the 70th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$73,065
Medicare patients
246
Services billed
2,454

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide114$129,599
JanuviaSitagliptin Phosphate89$91,078
EliquisApixaban65$50,204
XareltoRivaroxaban28$31,429
JardianceEmpagliflozin30$29,883
FarxigaDapagliflozin Propanediol41$29,375
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$25,864
RybelsusSemaglutide11$23,893
TradjentaLinagliptin26$20,127
LinzessLinaclotide28$19,303
TrulicityDulaglutide17$16,391
MounjaroTirzepatide15$15,590
Spiriva RespimatTiotropium Bromide18$14,861
Levemir FlexpenInsulin Detemir45$11,780
Tresiba Flextouch U-100Insulin Degludec25$11,696

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$156$153,491125 claims
MerckJanuvia$30$91,07889 claims
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat$13$64,87274 claims
PfizerEliquis$70$50,20465 claims
AstraZenecaFarxiga, Symbicort$115$32,07553 claims
Lilly USA, LLCTrulicity, Mounjaro$185$31,98132 claims
Johnson & JohnsonXarelto$12$31,42928 claims
GSKTrelegy Ellipta$257$25,86434 claims
AbbVieLinzess$141$19,30328 claims
NovartisEntresto$20$6,81011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Mobile

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →